Jan 12, 2026 07:06AM
Jan 12, 2026 07:00AM
Nov 12, 2025 04:01PM
Nov 10, 2025 07:00AM
Nov 10, 2025 07:00AM
Aug 12, 2025 04:01PM
Aug 12, 2025 07:02AM AN2 Therapeutics begins human trial for Chagas disease drug
Aug 12, 2025 07:00AM
Jul 23, 2025 07:00AM
Jul 23, 2025 07:00AM
Jun 30, 2025 07:02AM
Jun 30, 2025 07:00AM
May 13, 2025 04:01PM
May 1, 2025 04:00PM AN2 Therapeutics, Inc (ANTX) Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study
May 1, 2025 04:00PM
Mar 26, 2025 04:06AM
Mar 26, 2025 01:46AM
Mar 25, 2025 04:00PM
Feb 24, 2025 07:03AM
Feb 24, 2025 07:00AM
Feb 20, 2025 04:07AM Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Feb 3, 2025 04:13AM
Jan 28, 2025 05:42AM
Nov 18, 2024 02:43AM
Nov 13, 2024 04:00PM
Oct 17, 2024 07:03AM
Oct 17, 2024 07:00AM
May 14, 2024 04:01PM AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
Apr 2, 2024 03:37AM
Mar 28, 2024 04:10PM
Feb 12, 2024 06:45AM
Feb 12, 2024 06:45AM
Nov 9, 2023 04:05PM
Oct 11, 2023 12:01AM
Sep 13, 2023 07:00AM AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
Aug 10, 2023 04:10PM
Jul 5, 2023 07:18PM
Mar 29, 2023 04:01PM
Mar 24, 2023 01:18AM
Nov 9, 2022 04:05PM
Aug 11, 2022 04:10PM
Jun 29, 2022 07:00AM AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
May 10, 2022 04:10PM
Mar 4, 2022 04:10PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All